Shapiro et al.. “First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors.” Clinical Cancer Research. 21 October 2014. DOI: 10.1158/1078-0432.CCR-14-0979

/in ,

Summary

Purpose: AT13387 is a potent second-generation, fragment-derived HSP90 inhibitor. This phase I study investigated the maximum tolerated dose (MTD)/recommended phase II dose (RP2D) and safety, pharmacokinetic, and pharmacodynamic profiles of two AT13387 regimens in a refractory solid tumor population.

View further details below
Shapiro et al.. “First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors.” Clinical Cancer Research. 21 October 2014. DOI: 10.1158/1078-0432.CCR-14-0979